ArticleOncotarget2015
INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 48 citations in OpenAlex.
- Aryl hydrocarbon receptor promotes the proliferation and aggressive progression of colorectal cancer under high-fat diet via activating INPP4B/AKT/SGK3 signaling pathway.Frontiers in oncology · 2026Article
- Role of INPP4B in the proliferation, migration, invasion, and survival of human endometrial cancer cells.Histology and histopathology · 2024Article
- Inositol phosphatase INPP4B sustains ILC1s and intratumoral NK cells through an AKT-driven pathway.The Journal of experimental medicine · 2024Article
- Role of inositol polyphosphate-4-phosphatase type II in oncogenesis of digestive system tumors.World journal of gastrointestinal oncology · 2023Review
- Phosphoinositides in New Spaces.Cold Spring Harbor perspectives in biology · 2023Review
- Tumor Suppressor Role of INPP4B in Chemoresistant Retinoblastoma.Journal of oncology · 2023Article
- Genes regulated by DNA methylation are involved in distinct phenotypes during melanoma progression and are prognostic factors for patients.Molecular oncology · 2022Article
- INPP4B promotes PI3Kα-dependent late endosome formation and Wnt/β-catenin signaling in breast cancer.Nature communications · 2021Article
- Expression and functional characterization of INPP4B in gallbladder cancer patients and gallbladder cancer cells.BMC cancer · 2021Article
- Targeting SHIP1 and SHIP2 in Cancer.Cancers · 2021Review
- Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor in Multiple Myeloma.Frontiers in oncology · 2021Article
- Cylindromatosis Is Required for Survival of a Subset of Melanoma Cells.Oncology research · 2020Article
- Oocyte Maturation in Starfish.Cells · 2020Review
- Reprogramming of fatty acid metabolism in cancer.British journal of cancer · 2020Review
- Investigating the duality ofOncotarget · 2019Article
- INPP4B As A Prognostic And Diagnostic Marker Regulates Cell Growth Of Pancreatic Cancer Via Activating AKT.OncoTargets and therapy · 2019Article
- INPP4B inhibits cell proliferation, invasion and chemoresistance in human hepatocellular carcinoma.OncoTargets and therapy · 2019Article
- INPP4B promotes colorectal cancer cell proliferation by activating mTORC1 signaling and cap-dependent translation.OncoTargets and therapy · 2019Article
- miR-1290 Contributes to Colorectal Cancer Cell Proliferation by Targeting INPP4B.Oncology research · 2018Article
- MicroRNA-599 suppresses glioma progression by targeting RAB27B.Oncology letters · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inositol polyphosphate 4-phosphatase type II (INPP4B) negatively regulates PI3K/Akt signalling and has a tumour suppressive role in some types of cancers. However, we have found that it is upregulated in a subset of melanomas. Here we report that INPP4B can function as an oncogenic driver through activation of serum- and glucocorticoid-regulated kinase 3 (SGK3) in melanoma. While INPP4B knockdown inhibited melanoma cell proliferation and retarded melanoma xenograft growth, overexpression of INPP4B enhanced melanoma cell and melanocyte proliferation and triggered anchorage-independent growth of melanocytes. Noticeably, INPP4B-mediated melanoma cell proliferation was not related to activation of Akt, but was mediated by SGK3. Upregulation of INPP4B in melanoma cells was associated with loss of miRNA (miR)-494 and/or miR-599 due to gene copy number reduction. Indeed, overexpression of miR-494 or miR-599 downregulated INPP4B, reduced SGK3 activation, and inhibited melanoma cell proliferation, whereas introduction of anti-miR-494 or anti-miR-599 upregulated INPP4B, enhanced SGK3 activation, and promoted melanoma cell proliferation. Collectively, these results identify upregulation of INPP4B as an oncogenic mechanism through activation of SGK3 in a subset of melanomas, with implications for targeting INPP4B and restoring miR-494 and miR-599 as novel approaches in the treatment of melanomas with high INPP4B expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.